Market's view on Genedrive
Published on April 2024
- Genedrive has announced a partnership with International Biomedical for the distribution of their products in the USA, facilitating affordable access for clinical studies in NICU sites, which is crucial for FDA submission processes.
- Genedrive is actively participating in the 31st UNEKO National Neonatology Congress in Antalya, Turkey, promoting their Genedrive MT-RNR1 ID Kit.
- There are discussions about Genedrive’s Clinical Trial Agreement with a leading multi-state physician organisation in the USA to support clinical studies required for FDA regulatory approval of the Genedrive® MT-RNR1 ID Kit.
- Some stock watchers express concerns regarding the financial sustainability of Genedrive, mentioning potential risks with the current funding situation and the possibility of a share placing at a lower price.
- There is skepticism about the recent share price movement, with suggestions that it might be a manipulation before a potential financial downturn, referred to as a ‘death spiral finance situation’.
- Positive sentiments are also shared, with some watchers believing in the company’s progress and government support, despite the challenges and market conditions.